Similar articles

• Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.

  Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC. Lee DS, et al. Cancer J Sci Am. 1998 Mar-Apr;4(2):86-93. Cancer J Sci Am. 1998. PMID: 9532410 Clinical Trial.
• IL-2 therapy proves durable in renal cell melanoma patients.

  [No authors listed] [No authors listed] Oncology (Williston Park). 1991 Sep;5(9):71. Oncology (Williston Park). 1991. PMID: 1835879 Clinical Trial. No abstract available.
• Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.

  Négrier S. Négrier S. J Clin Oncol. 2004 Apr 1;22(7):1174-6. doi: 10.1200/JCO.2004.01.998. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981101 No abstract available.
• [Is interleukin 2 useful in oncology?].

  Négrier S. Négrier S. Rev Prat. 1998 Feb 1;48(3):237-9. Rev Prat. 1998. PMID: 9781067 Review. French. No abstract available.
• [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].

  van Herpen CM, de Mulder PH. van Herpen CM, et al. Ned Tijdschr Geneeskd. 1998 Nov 28;142(48):2613-8. Ned Tijdschr Geneeskd. 1998. PMID: 10028361 Review. Dutch.